Redefining Hypovolemic Shock

Sovateltide For Cerebral Ischemic Stroke

Serving Patients with neurodegenerative disorders

Developing endothelin based drug therapies

Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies

Pharmazz, Inc.

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.

Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

More About Us

Product Pipeline

Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Market
Sovateltide - Tycamzzi™ Acute Cerebral Ischemic Stroke
Hypoxic-Ischemic Encephalopathy
Alzheimer's Disease
Centhaquine - Lyfaquin® Hypovolemic Shock
COVID-19 with ARDS
Septic Shock


The management team is well balanced with significant drug development and clinical expertise, and commercialization experience. In addition to the management and development team in the US, the company has over 80 employees through its subsidiary in India.

More Details

Media Coverage


Centhaquine set to enter US-FDA approved Phase 3 clinical trial in US and Europe

By EP News Bureau On Aug 2, 2023 -- Centhaquine, a first-in-class drug developed by Pharmazz India, a majority-owned subsidiary..


First-ever Indian drug to get direct US FDA approval to enter ph 3 trials in US & EU

By BioSpectrum India On Aug 2, 2023 -- Pharmazz India, a majority-owned subsidiary of US-based Pharmazz, Inc. s first-in-class


Centhaquine to enter US FDA approved phase 3 clinical trial in US and Europe, says Pharmazz India

By Pharmabiz On Aug 2, 2023 -- Pharmazz India Private Limited, a majority-owned subsidiary of Pharmazz, Inc, has announced